Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Uwe Hehnke"'
Autor:
Uwe Hehnke, Jyothis T. George, David Fitchett, Silvio E. Inzucchi, Mikhail Kosiborod, Christoph Wanner, Stefan Kaspers, Bernard Zinman
Publikováno v:
Circulation. 138:1904-1907
Publikováno v:
Advances in Therapy
Introduction Asian patients with type 2 diabetes (T2D) are younger, leaner, and more likely to develop renal dysfunction than White populations. In this multiethnic analysis of data from phase 3 trials, we investigated the efficacy and safety of the
Publikováno v:
Diabetes, Obesity and Metabolism. 19:1620-1624
In the EMPA-REG BP trial, empagliflozin significantly reduced systolic and diastolic blood pressure (SBP and DBP) compared with placebo at week 12 in patients with type 2 diabetes mellitus (T2DM) and hypertension. In a post-hoc analysis, we assessed
Autor:
Uwe Hehnke, Thomas Meinicke, Mark E. Cooper, Audrey Koitka-Weber, Vlado Perkovic, Maximilian von Eynatten, Sandra van der Walt, Per-Henrik Groop, Berthold Hocher
Publikováno v:
Journal of Hypertension
Objective: Concomitant treatment with angiotensin-converting enzyme (ACE) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors is increasingly common. Pharmacological studies have suggested a potential adverse drug interaction between ACE inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d30077cea15637d6abcd8ce8bd3895c3
http://hdl.handle.net/10138/306381
http://hdl.handle.net/10138/306381
Autor:
Jisoo Lee, Stefan Kaspers, Silvio E. Inzucchi, Bernard Zinman, Jyothis T. George, Douglas Clark, C Wanner, Uwe Hehnke
Publikováno v:
Diabetes – Nicht nur eine Typ-Frage – www.diabeteskongress.de.
Autor:
Jisoo Lee, Sandra Thiemann, S Durán-Garcia, Hans-Juergen Woerle, Uwe Hehnke, Julio Rosenstock, Sanjay Patel, Hannele Yki-Järvinen
Publikováno v:
Diabetic Medicine. 33:926-933
Aim To evaluate the efficacy and safety of linagliptin in people with Type 2 diabetes inadequately controlled on basal insulin and metformin. Methods This was a post hoc subanalysis of participants who received basal insulin and metformin in a global
Autor:
Christopher P. Cannon, Darren K. McGuire, Steven Sambevski, Uwe Hehnke, Bernard Zinman, Jyothis T. George, Silvio E. Inzucchi, David Fitchett, O.E. Johansen
Publikováno v:
European Heart Journal. 39
Autor:
Benjamin M. Scirica, Uwe Hehnke, Darren K. McGuire, David Fitchett, Christopher P. Cannon, Jyothis T. George, Steven Sambevski, Silvio E. Inzucchi, Bernard Zinman, Odd Erik Johansen
Publikováno v:
Diabetes. 67
In the EMPA-REG OUTCOME trial, EMPA added to standard of care reduced CV death vs. placebo (PBO) by 38% (HR 0.62 [95% CI 0.49, 0.77]), all-cause death by 32% (HR 0.68 [95% CI 0.57, 0.82]) and HHF by 35% (HR 0.65 [95% CI 0.50, 0.85]) in patients with
Autor:
Silvio E. Inzucchi, Maximilian von Eynatten, Bernard Zinman, Uwe Hehnke, Mark E. Cooper, Audrey Koitka-Weber, Christoph Wanner
Publikováno v:
Diabetes. 67
The EMPA-REG OUTCOME trial demonstrated the renoprotective role of the sodium-glucose co-transporter 2 inhibitor empagliflozin (EMPA) by reducing the risk of incident or worsening nephropathy by 39% vs. placebo (PBO) in patients with T2DM and establi
Autor:
Bernard Zinman, Stefan Kaspers, Uwe Hehnke, Douglas Clark, Jyothis T. George, Silvio E. Inzucchi, Christoph Wanner, Isabella Zwiener
Publikováno v:
Diabetes care. 42(4)
Sodium–glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce cardiovascular (CV) events in CV outcome trials in patients with type 2 diabetes and CV disease. In BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Di